Limonene on Regulating Metabolism-related Fatty Liver Disease (MAFLD) and Analysis of TCM Constitution

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

February 22, 2021

Primary Completion Date

October 25, 2021

Study Completion Date

October 25, 2021

Conditions
Fatty Liver
Interventions
DRUG

Limonene capsule

All the recruiters will be given treatment under the guidance of basic diet. Basic dietary guidelines include high-quality protein and fresh green leafy vegetables. It need to controlled sugar, various sweets and high-calorie foods, frying and other foods with high oil content and foods with high cholesterol content. Limonene capsules group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo control group and limonene capsule administration group. The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the treatment group and the placebo control group at a ratio of 1:1. The drug was administered for 12 weeks, 3 times a day, 5 capsules each time.

DRUG

Limonene capsules(Placebo)

Limonene capsules(Placebo)

Trial Locations (1)

200032

Longhua Hospital, Shanghai

All Listed Sponsors
collaborator

Shanghai Shen Kang Hospital Development Center

OTHER

collaborator

Longhua Hospital

OTHER

collaborator

Hongqiao International Institute of Medicine, Shanghai Tongren Hospital and Faculty of Public Health, Shanghai Jiao Tong University School of Medicine

UNKNOWN

lead

Hongsheng Tan

OTHER

NCT04853082 - Limonene on Regulating Metabolism-related Fatty Liver Disease (MAFLD) and Analysis of TCM Constitution | Biotech Hunter | Biotech Hunter